Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:36:36 2024-07-05 pm EDT 5-day change 1st Jan Change
1.645 USD +0.30% Intraday chart for Ocugen, Inc. +5.75% +185.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Small Cap Completeness Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Microcap Growth Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2000 Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000E Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Microcap Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000 Growth Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000E Growth Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2000 Growth Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2000 Dynamic Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2500 Growth Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Small Cap Comp Growth Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2500 Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000 Index CI
Ocugen, Inc.(NasdaqCM:OCGN) added to S&P Biotechnology Select Industry Index CI
Sector Update: Health Care Stocks Steady Premarket Friday MT
Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate MT
Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease CI
Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400?First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication CI
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb MT
Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410 CI
Ramesh Kumar Announces Not to Stand for Re-Election to the Board of Ocugen, Inc CI
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study MT
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy CI
Transcript : Ocugen, Inc., Q1 2024 Earnings Call, May 14, 2024
Chart Ocugen, Inc.
More charts
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.64 USD
Average target price
6.667 USD
Spread / Average Target
+306.50%
Consensus